THE Federal Government has
joined with Apotex in a damages
case against Sanofi-Aventis,
claiming delays in generic versions
of clopidogrel (Plavix) has cost it
over $130 million a year.
The govt has allocated $1.2m
in the budget for costs related
to the legal action, with the
commonwealth’s application heard
in the Federal Court last Fri.
The long-running Apotex case
was initiated in 2007 when the
firm applied to have Sanofi’s patent
on clopidogrel revoked - but an
injunction stopped Apotex from
launching its own version of Plavix.
The injunction was reversed in
Mar 2010 and Apotex and the govt
are now claiming compensation for
damages incurred due to the delay.The above article was sent to subscribers in Pharmacy Daily's issue from 22 Apr 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 22 Apr 13
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.